We read with a great interest the report by Van Schie et al 1 which highlighted that the antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. The results described in this report confirm very clearly the results that we obtained recently.
The results obtained in this report are consistent with clinical data already published. In fact, several studies have reported an association between ADA production and reduced levels of TNF blockers. [2] [3] [4] This association can be partially explained by an increased drug clearance secondarily to the formation of immune complexes between ADAs and anti-TNF. 5 Clinically, the presence of ADAs is associated with a significantly higher risk of loss of clinical response to IFX, 6 7 reinforcing ADAs importance in terms of interference with drug action.
In conclusion, ADAs interest is increasing as many clinical and physiological studies have shown their importance in drug activity. As the majority of ADAs are neutralising, their monitoring during TNF blocker treatment seems to be highly relevant. More algorithms must be developed 8 9 regarding drug characteristics and the assay used for drug and ADA determination. Contributors MR-G, XR, HM, SP have performed the experiment and contributed to the redaction of the letter.
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